Here's Why Merck (MRK) is a Strong Value Stock

Company Overview - Merck & Co. is based in Kenilworth, NJ, and has over six blockbuster products, with Keytruda, a PD-L1 inhibitor, accounting for approximately 50% of its pharmaceutical sales [12] - Keytruda has significantly contributed to Merck's steady revenue growth in recent years, although there are concerns about the company's heavy reliance on this drug and the need for product diversification [12] Zacks Rank and Style Scores - Merck is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of B, indicating a solid position but not a strong buy [13] - The company has a Value Style Score of A, supported by attractive valuation metrics such as a forward P/E ratio of 8.92, which may appeal to value investors [13] - In the last 60 days, seven analysts have revised their earnings estimates higher for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.06 to $8.93 per share [13] - Merck has an average earnings surprise of +3.9%, suggesting a positive trend in earnings performance [13] Investment Considerations - With a solid Zacks Rank and top-tier Value and VGM Style Scores, Merck is recommended for investors' consideration [14]